Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2)

TM Maher; M Kreuter; DJ Lederer; KK Brown; W Wuyts; N Verbruggen; S Stutvoet; A Fieuw; P Ford; W Abi-Saab; Marlies Wijsenbeek - Lourens

doi:10.1136/bmjresp-2019-000422

Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2)

TM Maher
, M Kreuter
, DJ Lederer
, KK Brown
, W Wuyts
, N Verbruggen
, S Stutvoet
, A Fieuw
, P Ford
, W Abi-Saab
, Marlies Wijsenbeek - Lourens

Pulmonary Medicine

Research output: Contribution to journal › Article › Academic › peer-review

92 Citations (Scopus)

49 Downloads (Pure)

Original language	Undefined/Unknown
Article number	UNSP e000422
Journal	BMJ Open Respiratory Research
Volume	6
Issue number	1
DOIs	https://doi.org/10.1136/bmjresp-2019-000422
Publication status	Published - 2019

Research programs

EMC MM-04-42-02

Access to Document

10.1136/bmjresp-2019-000422

Repub_117705_O-A.pdfFinal published version, 365 KB

http://hdl.handle.net/1765/117705

Cite this

Maher, TM., Kreuter, M., Lederer, DJ., Brown, KK., Wuyts, W., Verbruggen, N., Stutvoet, S., Fieuw, A., Ford, P., Abi-Saab, W., & Wijsenbeek - Lourens, M. (2019). Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2). BMJ Open Respiratory Research, 6(1), Article UNSP e000422. https://doi.org/10.1136/bmjresp-2019-000422

@article{60a427509d2a456f81b40b5602db67e1,

title = "Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2)",

author = "TM Maher and M Kreuter and DJ Lederer and KK Brown and W Wuyts and N Verbruggen and S Stutvoet and A Fieuw and P Ford and W Abi-Saab and \{Wijsenbeek - Lourens\}, Marlies",

year = "2019",

doi = "10.1136/bmjresp-2019-000422",

language = "Undefined/Unknown",

volume = "6",

journal = "BMJ Open Respiratory Research",

issn = "2052-4439",

publisher = "BMJ Publishing Group",

number = "1",

}

Maher, TM, Kreuter, M, Lederer, DJ, Brown, KK, Wuyts, W, Verbruggen, N, Stutvoet, S, Fieuw, A, Ford, P, Abi-Saab, W & Wijsenbeek - Lourens, M 2019, 'Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2)', BMJ Open Respiratory Research, vol. 6, no. 1, UNSP e000422. https://doi.org/10.1136/bmjresp-2019-000422

Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2). / Maher, TM; Kreuter, M; Lederer, DJ et al.
In: BMJ Open Respiratory Research, Vol. 6, No. 1, UNSP e000422, 2019.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2)

AU - Maher, TM

AU - Kreuter, M

AU - Lederer, DJ

AU - Brown, KK

AU - Wuyts, W

AU - Verbruggen, N

AU - Stutvoet, S

AU - Fieuw, A

AU - Ford, P

AU - Abi-Saab, W

AU - Wijsenbeek - Lourens, Marlies

PY - 2019

Y1 - 2019

U2 - 10.1136/bmjresp-2019-000422

DO - 10.1136/bmjresp-2019-000422

M3 - Article

C2 - 31179008

SN - 2052-4439

VL - 6

JO - BMJ Open Respiratory Research

JF - BMJ Open Respiratory Research

IS - 1

M1 - UNSP e000422

ER -